Management of Associated Rheumatoid Arthritis and Fibromyalgia

THEODORE PINCUS

J Rheumatol 2009;36;2123
http://www.jrheum.org/content/36/9/2123.2

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Management of Associated Rheumatoid Arthritis and Fibromyalgia

To the Editor:

The interesting report of Coury and colleagues1, and thoughtful accompanying editorial by Mäkinen and Hannonen2, call attention to the important problem of fibromyalgia (FM) in patients with rheumatoid arthritis (RA).

Patient self-report questionnaire data for pain, fatigue, or patient global estimate, the patient measure that is included in the DAS283, are usually high in patients with FM or FM and RA. The self-report scores often appear to health professionals disproportionately high in patients with FM and RA relative to “objective” data from a joint examination or laboratory tests. For example, Coury, et al1 suggest that “DAS28 overestimates the true status of patients with RA who also have FM” (emphasis added by this author).

An alternative approach is to regard anything written or reported by a patient as “true,” although the response may suggest higher levels of inflammatory activity than might be present. Apparently disproportionate high scores, as interpreted by the clinician, in patients who might have FM or RA or another rheumatic disease might be regarded as a clue in diagnosis. This approach is reflected in the January 2009 issue in an article by Wolfe, et al4 on complexities in evaluation of systemic lupus erythematosus (SLE) activity in patients with both FM and SLE.

We have reported 3 phenomena regarding self-report responses on a multidimensional health assessment questionnaire (MDHAQ)5 in patients with FM: a high ratio of pain to functional disability scores6, a high ratio of fatigue to functional disability scores7, and a high number of symptoms on a review of systems7. These measures appear as effective as a sedimentation rate to distinguish patients with RA from patients with FM6,7. We did not report on patients with RA and FM, but subsequent clinical experience has indicated particular value in patients with FM who meet criteria for RA or another rheumatic disease.

The reported “clues” certainly are not 100% diagnostic, as is the case with all rheumatology measures. For example, a substantial rise in erythrocyte sedimentation rate in a patient with RA may indicate an infection or lymphoma, rather than a disease flare. All rheumatology measures, including laboratory tests and patient questionnaire responses, require interpretation by a thoughtful and caring clinician.

All the measures reported as “clues” to FM are included on the simple one-page MDHAQ5. FM is primarily a patient-reported syndrome, and patient self-report appears a most effective way to identify patients, particularly patients who meet criteria for concomitant inflammatory diseases, such as RA and SLE. We continue to advocate routine use of the MDHAQ8 at all visits of all patients seen by a rheumatologist.

THEODORE PINCUS, MD. New York University Hospital for Joint Diseases, 301 East 17th Street, New York 10003, New York, USA.

Address correspondence to Dr. T. Pincus; E-mail: tedpincus@gmail.com

REFERENCES


J Rheumatol 2009;36:9; doi:10.3899/jrheum.090336